In parallel, Jayasena et al. [14] and Abbara et al. [15] investigated kisspeptin as a trigger in women at high risk of OHSS, confirming its safety and efficacy with both single- and double-dose regimens. The gene discussed is KISS1; the disease is ovarian hyperstimulation syndrome.